Literature DB >> 15700269

The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes.

Helen K Berrieman1, Laura Smith, Sara L O'Kane, Anne Campbell, Michael J Lind, Lynn Cawkwell.   

Abstract

BACKGROUND: Proteins of the Bcl-2 family play a key role in the control of apoptosis and carry out both proapoptotic and antiapoptotic functions. However, with the exception of Bcl-2 itself, little is known about the expression of these potentially critical proteins in nonsmall cell lung carcinoma.
METHODS: Immunohistochemistry was used to study the expression of Bcl-2 and 6 other Bcl-2 family proteins in a pilot series of 41 archival nonsmall cell lung carcinoma specimens (19 adenocarcinomas and 22 squamous cell carcinomas).
RESULTS: Overexpression of the apoptosis inhibitors Bcl-2 and Bcl-X(L) was observed in 10 of 41 samples (24%) and in 11 of 41 samples (27%), respectively. Loss of expression of proapoptotic proteins was observed as follows: Bak, 24 of 41 samples (59%); Bad, 21 of 41 samples (51%); Bid, 20 of 41 samples (49%); Bax, 14 of 41 samples (34%); and Bim/Bod, 2 of 41 samples (5%). Statistically significant differences in expression between adenocarcinoma samples and squamous cell carcinoma samples were observed for Bcl-X(L) (overexpression in 11 of 19 adenocarcinomas [58%] vs. 0 of 22 squamous cell carcinomas [0%]; P < 0.001) and for Bad (loss of expression in 5 of 19 adenocarcinomas [26%] vs. 16 of 22 squamous cell carcinomas [73%]; P = 0.004).
CONCLUSIONS: Although this was only a pilot study, the results revealed significant differences in the expression of apoptosis-related proteins both between individual samples of nonsmall cell lung carcinoma and between the two main histologic subtypes. Such differences may play a role in the development of lung tumors; and, if it is found that these differences are of clinical importance, then it may be required to regard nonsmall cell lung carcinoma subtypes as separate entities rather than as one disease. Copyright 2005 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15700269     DOI: 10.1002/cncr.20907

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Pharmacological manipulation of Bcl-2 family members to control cell death.

Authors:  Anthony Letai
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  Overexpression of Bcl-2-associated death inhibits A549 cell growth in vitro and in vivo.

Authors:  Na Huang; Jing Zhu; Dan Liu; Ya-Lun Li; Bo-Jiang Chen; Yan-Qi He; Kun Liu; Xian-Ming Mo; Wei-Min Li
Journal:  Cancer Biother Radiopharm       Date:  2011-10-19       Impact factor: 3.099

3.  BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.

Authors:  Zhanxia Li; Songwen Zhou; Ling Zhang; Chunxia Su; Jinqin Hang; Yinmin Zhao; Bo Su; Caicun Zhou
Journal:  Med Oncol       Date:  2010-03-17       Impact factor: 3.064

4.  Deregulated BCL-2 family proteins impact on repair of DNA double-strand breaks and are targets to overcome radioresistance in lung cancer.

Authors:  Sarah A Wieczorek; Frank Breitenbuecher; Aashish Soni; Katja Paul-Konietzko; Sophie Ziegler; Ali Sak; George Iliakis; Martin Schuler
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-21       Impact factor: 4.553

5.  Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.

Authors:  Alberto Chiappori; Charles Williams; Donald W Northfelt; John W Adams; Shakun Malik; Martin J Edelman; Peter Rosen; David A Van Echo; Mark S Berger; Eric B Haura
Journal:  J Thorac Oncol       Date:  2014-01       Impact factor: 15.609

Review 6.  Apoptosis block as a barrier to effective therapy in non small cell lung cancer.

Authors:  Ian Paul; J Mark Jones
Journal:  World J Clin Oncol       Date:  2014-10-10

7.  Expression of Bim, Noxa, and Puma in non-small cell lung cancer.

Authors:  Jun Sakakibara-Konishi; Satoshi Oizumi; Junko Kikuchi; Eiki Kikuchi; Hidenori Mizugaki; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura
Journal:  BMC Cancer       Date:  2012-07-12       Impact factor: 4.430

8.  Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis.

Authors:  Shankar Varadarajan; Michael Butterworth; Jun Wei; Maurizio Pellecchia; David Dinsdale; Gerald M Cohen
Journal:  Neoplasia       Date:  2013-05       Impact factor: 5.715

9.  Novel Nanoliposomes Alleviate Contrast-Induced Nephropathy by Mediating Apoptosis Response in New Zealand Rabbits.

Authors:  Peng Zhang; Xue Zhang; Jing Zhang; Yanqiu Song; Ting Liu; Zhican Zeng; Xiaofeng Fu; Han Fu; Hong Zhang; Qin Qin; Naikuan Fu; Zhigang Guo
Journal:  Front Mol Biosci       Date:  2021-07-06

10.  Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer.

Authors:  I Paul; A D Chacko; I Stasik; S Busacca; N Crawford; F McCoy; N McTavish; B Wilson; M Barr; K J O'Byrne; D B Longley; D A Fennell
Journal:  Cell Death Dis       Date:  2012-12-20       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.